These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 23703868)

  • 1. Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats.
    Rosado E; Rodríguez-Vilarrupla A; Gracia-Sancho J; Tripathi D; García-Calderó H; Bosch J; García-Pagán JC
    Hepatology; 2013 Oct; 58(4):1424-35. PubMed ID: 23703868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
    Di Pascoli M; Diví M; Rodríguez-Vilarrupla A; Rosado E; Gracia-Sancho J; Vilaseca M; Bosch J; García-Pagán JC
    J Hepatol; 2013 May; 58(5):904-10. PubMed ID: 23262250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats.
    Guillaume M; Rodriguez-Vilarrupla A; Gracia-Sancho J; Rosado E; Mancini A; Bosch J; Garcia-Pagán JC
    J Hepatol; 2013 Feb; 58(2):240-6. PubMed ID: 22989570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats.
    Coll M; Rodriguez S; Raurell I; Ezkurdia N; Brull A; Augustin S; Guardia J; Esteban R; Martell M; Genescà J
    Hepatology; 2012 Nov; 56(5):1849-60. PubMed ID: 22610782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase.
    Trebicka J; Hennenberg M; Laleman W; Shelest N; Biecker E; Schepke M; Nevens F; Sauerbruch T; Heller J
    Hepatology; 2007 Jul; 46(1):242-53. PubMed ID: 17596891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl
    Zhang R; Chen J; Liu D; Wang Y
    Front Med; 2019 Jun; 13(3):398-408. PubMed ID: 30820806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats.
    Rodríguez S; Raurell I; Torres-Arauz M; García-Lezana T; Genescà J; Martell M
    Sci Rep; 2017 Jan; 7():40461. PubMed ID: 28084470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis.
    Delgado MG; Gracia-Sancho J; Marrone G; Rodríguez-Vilarrupla A; Deulofeu R; Abraldes JG; Bosch J; García-Pagán JC
    Am J Physiol Gastrointest Liver Physiol; 2013 Oct; 305(7):G496-502. PubMed ID: 23886859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis.
    Zhang CG; Zhang B; Deng WS; Duan M; Chen W; Wu ZY
    World J Gastroenterol; 2016 May; 22(18):4484-500. PubMed ID: 27182159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.
    Klein S; Rick J; Lehmann J; Schierwagen R; Schierwagen IG; Verbeke L; Hittatiya K; Uschner FE; Manekeller S; Strassburg CP; Wagner KU; Sayeski PP; Wolf D; Laleman W; Sauerbruch T; Trebicka J
    Gut; 2017 Jan; 66(1):145-155. PubMed ID: 26385087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between endotoxemia and hepatic endocannabinoids in cirrhotic rats with portal hypertension.
    Lin HC; Yang YY; Tsai TH; Huang CM; Huang YT; Lee FY; Liu TT; Lee SD
    J Hepatol; 2011 Jun; 54(6):1145-53. PubMed ID: 21145843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposome-mediated gene transfer of endothelial nitric oxide synthase to cirrhotic rat liver decreases intrahepatic vascular resistance.
    Zhang ZQ; Qiu JF; Luo M; Sun YW; Zhao G; Chen W; Liu H; Wu ZY
    J Gastroenterol Hepatol; 2008 Aug; 23(8 Pt 2):e487-93. PubMed ID: 18070013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metformin reduces hepatic resistance and portal pressure in cirrhotic rats.
    Tripathi DM; Erice E; Lafoz E; García-Calderó H; Sarin SK; Bosch J; Gracia-Sancho J; García-Pagán JC
    Am J Physiol Gastrointest Liver Physiol; 2015 Sep; 309(5):G301-9. PubMed ID: 26138461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute effects of endothelin receptor antagonists on hepatic hemodynamics of cirrhotic and noncirrhotic rats.
    Cavasin MA; Semus H; Pitts K; Peng Y; Sandoval J; Chapo J; Plato CF
    Can J Physiol Pharmacol; 2010 Jun; 88(6):636-43. PubMed ID: 20628429
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model.
    Hu L; Su L; Dong Z; Wu Y; Lv Y; George J; Wang J
    J Mol Med (Berl); 2019 Mar; 97(3):423-434. PubMed ID: 30721324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amiloride reduces portal hypertension in rat liver cirrhosis.
    Steib CJ; Hennenberg M; Beitinger F; Hartmann AC; Bystron M; De Toni EN; Gerbes AL
    Gut; 2010 Jun; 59(6):827-36. PubMed ID: 20551467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis.
    Zhou Q; Hennenberg M; Trebicka J; Jochem K; Leifeld L; Biecker E; Sauerbruch T; Heller J
    Gut; 2006 Sep; 55(9):1296-305. PubMed ID: 16492715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic administration of ursodeoxycholic acid decreases portal pressure in rats with biliary cirrhosis.
    Yang YY; Huang YT; Lee KC; Lee FY; Lee TY; Hou MC; Lin HC; Lee SD
    Clin Sci (Lond); 2009 Jan; 116(1):71-9. PubMed ID: 18479249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antagonism of sphingosine 1-phosphate receptor 2 causes a selective reduction of portal vein pressure in bile duct-ligated rodents.
    Kageyama Y; Ikeda H; Watanabe N; Nagamine M; Kusumoto Y; Yashiro M; Satoh Y; Shimosawa T; Shinozaki K; Tomiya T; Inoue Y; Nishikawa T; Ohtomo N; Tanoue Y; Yokota H; Koyama T; Ishimaru K; Okamoto Y; Takuwa Y; Koike K; Yatomi Y
    Hepatology; 2012 Oct; 56(4):1427-38. PubMed ID: 22505286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabinoid receptor 2 agonist ameliorates mesenteric angiogenesis and portosystemic collaterals in cirrhotic rats.
    Huang HC; Wang SS; Hsin IF; Chang CC; Lee FY; Lin HC; Chuang CL; Lee JY; Hsieh HG; Lee SD
    Hepatology; 2012 Jul; 56(1):248-58. PubMed ID: 22290687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.